We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » CDRH Seeks Participants for Manufacturing and Product Quality Pilot Program

CDRH Seeks Participants for Manufacturing and Product Quality Pilot Program

January 19, 2018

CDRH is looking to enroll a total of nine participants in its new pilot program aimed at identifying best practices for quality product manufacturing.

The center, which began accepting applications for the Case for Quality Voluntary Medical Device Manufacturing and Product Quality Pilot Program on Jan. 2, intends to select manufacturers that can represent the medical device industry.

Participants must have remained in good FDA compliance during the last five years, and they must agree to: Appraisals conducted by the CMMI Institute; collecting and submitting metric data; being available for real-time consultations; participating in monitoring activities; and allowing the institute to report performance data analyses to the FDA.

Data collected throughout the duration of the pilot, which will run until Dec. 28, may also be used “to help determine if changes to the pilot program need to be made, de-identify data for benchmarking and trending, and to adjust any benefits to the firms where appropriate,” FDA spokesperson Deborah Kotz told FDAnews.

Participants will work in collaboration with the institute, agency staff, and the Medical Device Innovation Consortium (MDIC), which collectively developed the Capability Maturity Model Integration (CMMI) system, a maturity and appraisal program for the medical device industry.

The CMMI system’s goal is to “help organizations discover the true value they can deliver by building capability in their people and processes,” the FDA said. It has been “successfully used in various industries, including information technology, healthcare, automotive, defense, and aerospace to consistently deliver high quality products and reduce waste and defects,” the agency said.

According to the MDIC, there are several benefits for participating companies, such as having products reach the market at a faster pace, as well as improving resource allocation. Boston Scientific estimated participating in this program could have allowed it to redeploy $500,000 of resources assigned for the 69 30-day notices it submitted in 2016, the consortium said.

The CfQ Program was also designed to benefit the FDA by potentially reducing the allocation of resources, as participating firms can get inspection waivers.

“The idea of just routinely going out to do an audit for a company doing quite well...is probably not the best utilization of the agency’s limited resources,” Robin Newman, director at CDRH’s Office of Compliance said during the 2017 CfQ program workshop.

“It would be much better to go out and use those resources in areas where situations are not under control.”

View today's stories

Medical Devices Quality Regulatory Affairs QSR Inspections and Audits

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • AstraZeneca

    AstraZeneca Withdraws Imfinzi’s Bladder Cancer Indication

  • CE mark

    Cue Health’s COVID-19 Test Receives CE Mark

  • Sanofi-Regeneron_Logos.png

    Sanofi’s and Regeneron’s Libtayo Wins FDA Approval for NSCLC

  • PerkinElmer logo

    PerkinElmer’s Rapid Point-of-Care COVID-19 Test Cleared in Europe

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing